Reimbursed Care Access in Yemen

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Yemen’s national narcotics law prohibits importation, possession, manufacture and distribution of scheduled psychotropic substances except where expressly authorized by statute, and there is no publicly available record of a national medical program or reimbursement for psilocybin products. #.

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. There is no evidence of national approval, clinical‑use guidance, or reimbursement pathways for MDMA‑assisted therapy in Yemen. #.

No public record was found of national regulatory authorization, market registration, or a reimbursement pathway for esketamine (Spravato®) in Yemen. New branded psychedelic‑derived pharmaceuticals typically require explicit national marketing authorization and inclusion on national procurement/reimbursement lists to be available through public health programs; Yemen’s narcotics and medicines regulatory oversight framework restricts controlled substances to authorized medical uses only and there is no publicly available Yemeni listing showing esketamine authorization or public reimbursement. Clinical availability therefore appears absent and reimbursement is not established. # #.

Ketamine is recognized internationally as an essential injectable anaesthetic and is listed on the World Health Organization’s Model List of Essential Medicines for use in health systems; this status underpins its routine authorization and clinical use in many countries for anaesthesia and emergency medicine. #.

Under Yemen’s Law on Control and Illicit Trafficking and Abuse of Narcotics and Psychotropic Substances, controlled drugs may be imported, registered and used for medical purposes when authorized by law and in compliance with registration/notification requirements; this legal framework provides the pathway by which anesthetic agents such as ketamine would be lawfully used within hospitals and licensed facilities in Yemen, subject to ministry/regulatory controls. There is no public, centralized Yemeni medicines registry published online that documents a national reimbursement schedule for ketamine for psychiatric (off‑label) indications; in practice in low‑resource and conflict‑affected settings (including Yemen), ketamine’s primary and documented use is for procedural anesthesia and emergency care rather than reimbursed psychiatric administration. # #.

Practical implications: (1) Ketamine is lawfully used in clinical/operative contexts when properly procured and authorized by health authorities; (2) there is no published evidence of a national reimbursement program for ketamine when used off‑label for psychiatric indications in Yemen; (3) any use outside authorized medical settings (recreational possession, unlicensed clinics) would be contrary to Yemeni narcotics law. # #.

Currently classified as a strictly controlled substance under national and international scheduling frameworks, with no authorized medical use outside of approved clinical research in Yemen. DMT is internationally controlled under the 1971 Psychotropic Convention and national legislation in Yemen prohibits unsanctioned importation, possession and distribution of scheduled psychotropic substances; there is no public information indicating lawful medical or reimbursed therapeutic programs involving DMT in Yemen. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws with no authorized medical use outside approved clinical research in Yemen. There is no publicly available regulatory pathway, approval, or reimbursement for 5‑MeO‑DMT in Yemen. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no publicly available evidence of authorized ibogaine provision or reimbursement in Yemen. #.

Currently classified as a strictly controlled substance under national drug scheduling laws with no authorized medical use outside of approved clinical research; while plant materials themselves occupy a complex international legal position, preparations containing DMT are subject to national control and Yemen’s narcotics legislation prohibits unsanctioned manufacture, import and use. There is no evidence of lawful religious or therapeutic exemptions for ayahuasca or ayahuasca preparations in Yemen. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing cacti would be regulated under Yemen’s controlled substances framework when prepared or intended for consumption; there is no public record of medical programs or reimbursement for mescaline in Yemen. #.

Currently classified as a strictly controlled substance (or analogue) under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Novel phenethylamine psychedelics in the 2C family are commonly scheduled by national laws worldwide and Yemen’s narcotics law prohibits unsanctioned possession, manufacture and distribution; no authorized medical use or reimbursement for 2C‑X compounds is documented in Yemen. #.